ライフサイエンスコーパス: interleukin-1 receptor

1 ream of multiple Toll-like receptors and the interleukin-1 receptor.

2 ner dependent on signaling downstream of the interleukin-1 receptor.

3 s the key signaling adapter of Toll-like and interleukin-1 receptors.

4 or the upstream mediator of its expression, interleukin 1 receptor 1.

5 In the amygdala significant up-regulation of interleukin-1 receptor 1 (IL1r1), interleukin-4 receptor

6 The 28-kDa form of IL-1beta cannot activate interleukin-1 receptor-1 (IL1R1) to signal inflammatory

7 terleukin-6) and alloimmune activation (CD3, interleukin-1 receptor 2, programmed cell death-1, and s

8 rferon-gamma, interleukin-6) and alloimmune (interleukin-1 receptor 2, programmed cell death-1, and s

9 013) describe a molecular system implicating interleukin-1 receptor-2 (IL-1R2) as a principal cytosol

10 to caspase proteolytic activity that cleaves interleukin-1 receptor-2, allowing IL-1alpha dissociatio

11 n assays show that IL-1alpha associates with interleukin-1 receptor-2, and this association is decrea

12 in 1 pathway, through either ablation of the interleukin 1 receptor 8 (IL-1R8, also known as SIGIRR o

13 Interleukin-1 receptor 8 (IL-1R8, also known as single i

14 elated (SIGIRR), which is also known as Toll/interleukin-1 receptor 8 (TIR-8), is a member of the TIR

15 rinsic to B cells and was independent of the interleukin-1 receptor, a cytokine receptor that also si

16 The interleukin 1 receptor accessory protein (IL1RAP; IL1R3)

17 Interleukin-1 receptor accessory protein (IL1RAP; IL1R3)

18 Mutations and deletions of the interleukin-1 receptor accessory protein like 1 (IL1RAPL

19 the X-linked intellectual disability protein interleukin-1 receptor accessory protein like 1 (IL1RAPL

20 E) epsilon4 status was identified in IL1RAP (interleukin-1 receptor accessory protein; rs12053868-G;

21 ude myeloid differentiation protein (MyD88), interleukin-1 receptor-activated kinase-1, and TNF recep

22 e signal transduction pathways after TLR and interleukin-1 receptor activation.

23 ndings broaden our understanding of how Toll/interleukin-1 receptor adaptor proteins may participate

24 TLR2 and TLR4 signal via the Toll/interleukin-1 receptor adaptors MyD88 and MAL, leading t

25 EGF), basic fibroblast growth factor (bFGF), interleukin-1 receptor alpha (IL-1Ralpha), IL-6, IL-8, V

26 IRAK-4 and MyD88 deficiencies impair interleukin 1 receptor and Toll-like receptor (TLR) sign

27 rotein 3) inflammasome signaling through the interleukin-1 receptor and its signaling protein myeloid

28 h rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and

29 Serum interleukin 1 receptor antagonist (IL-1RA) levels were e

30 centrations of interleukin 1beta (IL-1beta), interleukin 1 receptor antagonist (IL-1Ra), and granuloc

31 lymorphisms of interleukin 1 beta (IL1B) and interleukin 1 receptor antagonist (IL1RA) genes for asso

32 rogation of the MSC transcriptome identified interleukin 1 receptor antagonist (IL1RN) as a potential

33 nd, even more importantly, anti-inflammatory interleukin 1 receptor antagonist (IL1Rn).

34 d P = .00005 for IMI, by the log-rank test), interleukin 1 receptor antagonist (IL1RN; rs419598; P =

35 Finally, inclusion of interleukin 1 receptor antagonist (Kineret(R)) in the ad

36 nduced protein [IP-10]) and proinflammatory (interleukin 1 receptor antagonist [IL-1RA], IL-6) cytoki

37 sis revealed an inverse relationship between interleukin 1 receptor antagonist and colony-stimulating

38 itric oxide synthase, interleukin-1beta, and interleukin 1 receptor antagonist but not transforming g

39 tory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease i

40 Potential immune markers, including interleukin 1 receptor antagonist, interferon gamma-indu

41 Tear concentrations increased for interleukin-1 receptor antagonist (16 557.1 +/- 4047.8 v

42 the impact of an exogenous recombinant human interleukin-1 receptor antagonist (anakinra) in experime

43 multifocal osteomyelitis, deficiency of the interleukin-1 receptor antagonist (DIRA), Majeed syndrom

44 Highly concentrated human recombinant interleukin-1 receptor antagonist (IL-1ra) aggregates at

45 lute partial correlation coefficients >0.40: Interleukin-1 receptor antagonist (IL-1Ra) and IL-8.

46 f the folded and unfolded ensembles of human interleukin-1 receptor antagonist (IL-1ra) are strongly

47 ty of the method was demonstrated with human interleukin-1 receptor antagonist (IL-1ra) as a protein

48 Interleukin-1 receptor antagonist (IL-1Ra) deficiency is

49 Interleukin-1 receptor antagonist (IL-1Ra) has been eval

50 L-1beta and its regulation by the endogenous interleukin-1 receptor antagonist (IL-1ra) in glutamate

51 We therefore examined the influence of interleukin-1 receptor antagonist (IL-1Ra) on MCL healin

52 e investigated whether the anti-inflammatory interleukin-1 receptor antagonist (IL-1Ra) prevents muri

53 itors enhance the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) secretion in

54 production of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA) that could be

55 and structural behavior of human recombinant interleukin-1 receptor antagonist (IL-1ra) was revealed

56 Notably, the hepatic expression of interleukin-1 receptor antagonist (IL-1ra) was suppresse

57 Levels of interleukin-1 receptor antagonist (IL-1Ra) were determin

58 necrosis factor (TNF) receptor-2 (TNFR2) and interleukin-1 receptor antagonist (IL-1ra) were fused to

59 Structural properties and folding of interleukin-1 receptor antagonist (IL-1ra), a therapeuti

60 The endogenous interleukin-1 receptor antagonist (IL-1Ra), an inflammat

61 culating levels of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1Ra), and soluble

62 so occurred, with GVHD-specific secretion of interleukin-1 receptor antagonist (IL-1Ra), IL-18, and C

63 otype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA).

64 experiments using recombinant type I IFN and interleukin-1 receptor antagonist (IL-1ra).

65 at a single intracisternal administration of interleukin-1 receptor antagonist (IL-1RA; 112 mug) at t

66 sma levels of neopterin (P<;0.0001), soluble interleukin-1 receptor antagonist (P<;0.0001), IL-8 (P=0

67 Recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and the lig

68 nd methionine oxidation in recombinant human interleukin-1 receptor antagonist (rhIL-1ra) was investi

69 interleukin-10 (IL-10), and increased plasma interleukin-1 receptor antagonist (sIL-1ra) and soluble

70 D and confirmed six proteins (leptin, renin, interleukin-1 receptor antagonist [IL-1ra], hepatocyte g

71 etanercept, infliximab, and adalimumab), the interleukin-1 receptor antagonist anakinra, and to a muc

72 that can be blocked by administration of an interleukin-1 receptor antagonist and a specific p38 MAP

73 The biologic agents interleukin-1 receptor antagonist and antitumor necrosis

74 3), and antiinflammatory markers (increased interleukin-1 receptor antagonist and lower monocyte and

75 py efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDS

76 Recent studies have also focused on the interleukin-1 receptor antagonist and the melanocortin-1

77 -alpha), interleukin-6 (IL-6), IL-1beta, and interleukin-1 receptor antagonist but not IL-12 and indu

78 rosis factor-alpha and interleukin-6 and the interleukin-1 receptor antagonist compared with control

79 Experimental interleukin-1 receptor antagonist gene overexpression ha

80 ntagonist gene overexpression has shown that interleukin-1 receptor antagonist is cardioprotective du

81 l activation by minocycline or by transgenic interleukin-1 receptor antagonist overexpression rescued

82 in plasma interleukin-8, interleukin-10, and interleukin-1 receptor antagonist posttransfusion compar

83 Systemic delivery of interleukin-1 receptor antagonist protected SN DA neuron

84 The use of an interleukin-1 receptor antagonist to control wound pain

85 akinra is a recombinant version of the human interleukin-1 receptor antagonist used to treat autoinfl

86 nd 2, C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist were measured in 233 i

87 or necrosis factor-alpha, interleukin-6, and interleukin-1 receptor antagonist), their mRNA expressio

88 occurring antiinflammatory cytokine IL-1Ra (interleukin-1 receptor antagonist).

89 associated with augmented concentrations of interleukin-1 receptor antagonist, a key anti-inflammato

90 of TNF-alpha, interleukin-6, interleukin-8, interleukin-1 receptor antagonist, and interleukin-10 in

91 alpha2beta1 integrin polyclonal antibodies, interleukin-1 receptor antagonist, and the chemical inhi

92 interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved beta-cell fu

93 The temporal patterns of interleukin-1 receptor antagonist, intercellular adhesio

94 We investigated the effects of anakinra, an interleukin-1 receptor antagonist, on coronary and left

95 Component 1 (interleukin-1 receptor antagonist, QA, and kynurenine) w

96 ed growth factor receptors, and anakinra, an interleukin-1 receptor antagonist, respectively, increas

97 Interleukin-1 receptor antagonist-deficient (Il1rn-/-) B

98 ly attenuated by treatment with anakinra, an interleukin-1 receptor antagonist.

99 eating glutathione peroxidase 1 mice with an interleukin-1 receptor antagonist.

100 effects are prevented by pre-application of interleukin-1 receptor antagonist.

101 atinase-associated lipocalin, protein C, and interleukin-1 receptor antagonist.

102 secretion of tumor necrosis factor alpha and interleukin-1 receptor antagonist.

103 We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhi

104 ble CIAS1 mutations) to receive anakinra, an interleukin-1-receptor antagonist (1 to 2 mg per kilogra

105 ily members, including the gene encoding the interleukin-1-receptor antagonist (IL1RN).

106 The absence of interleukin-1-receptor antagonist allows unopposed actio

107 to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first

108 We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote th

109 sed by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involv

110 regulation of 2 inhibitors of TLR signaling: Interleukin 1 Receptor Associated Kinase (IRAK) M, and S

111 gh tyrosine nitration-mediated impairment of interleukin-1 receptor associated kinase (IRAK)4, a sign

112 a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using

113 s undertaken to test the candidacy of IRAK1 (interleukin-1 receptor associated kinase-1) as an X chro

114 canonical downstream signaling intermediates interleukin 1 receptor-associated kinase (IRAK) and Ikap

115 n primary murine macrophages, dependent upon interleukin 1 receptor-associated kinase (IRAK-1).

116 mammals and overlaps with the 5' UTR of the interleukin 1 receptor-associated kinase (IRAK1) gene.

117 of EGFR and the NF-kappaB regulatory kinase interleukin 1 receptor-associated kinase 1 (IRAK-1).

118 This included a Phe196Ser change in the interleukin 1 receptor-associated kinase 1 (IRAK1).

119 Interleukin 1 receptor-associated kinase 1(IRAK1), a key

120 We also demonstrate that MyD88, interleukin 1 receptor-associated kinase 1, and tumor ne

121 mber 6, and rhophilin 2) and three proteins (interleukin 1 receptor-associated kinase-like 2, glutama

122 In particular, a family of four interleukin 1 receptor-associated kinases (IRAK) regulat

123 Interleukin-1 receptor-associated kinase (IRAK) -1 plays

124 pathway involving the MyD88 adapter and the interleukin-1 receptor-associated kinase (IRAK) complex.

125 IRAK2, a member of the interleukin-1 receptor-associated kinase (IRAK) family,

126 nes encoding non-RD kinases belonging to the interleukin-1 receptor-associated kinase (IRAK) family.

127 pretreatment in vivo inhibited expression of interleukin-1 receptor-associated kinase (IRAK)-1 while

128 , antisense JNK and dominant negative MyD88, interleukin-1 receptor-associated kinase (IRAK)-1, IRAK4

129 Here, we show that the interleukin-1 receptor-associated kinase (IRAK)/Pelle-li

130 receptor-4 (TLR4) and its signaling molecule interleukin-1 receptor-associated kinase (IRAK-1) play a

131 s study, we examined the contribution of the interleukin-1 receptor-associated kinase 1 (IRAK-1) to L

132 id differentiation primary response (MyD88), interleukin-1 receptor-associated kinase 1 (IRAK-1), and

133 ion with NF-kappaB-inducing kinase (NIK) and interleukin-1 receptor-associated kinase 1 (IRAK-1), deg

134 Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is ov

135 Inhibition of BTK or interleukin-1 receptor-associated kinase 1 and 4 (IRAK-1

136 use of TMP with Bruton's tyrosine kinase or interleukin-1 receptor-associated kinase 1 and 4 inhibit

137 74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1)

138 rvival pathway, leading to downregulation of interleukin-1 receptor-associated kinase 1.

139 rvival pathway, leading to downregulation of interleukin-1 receptor-associated kinase 1.

140 ed NFkappaB activation, via interaction with interleukin-1 receptor-associated kinase 2 (IRAK2).

141 B cells isolated from patients deficient for interleukin-1 receptor-associated kinase 4 (IRAK-4), mye

142 onse was reversed in the patient, but not in interleukin-1 receptor-associated kinase 4 (IRAK-4)-defi

143 Interleukin-1 receptor-associated kinase 4 (IRAK4) plays

144 ying very rare loss-of-function mutations in interleukin-1 receptor-associated kinase 4 (IRAK4), a cr

145 Interleukin-1 receptor-associated kinase 4 (IRAK4), a ma

146 diminished degradation and interaction with interleukin-1 receptor-associated kinase 4 (IRAK4).

147 he Toll-like receptor (TLR) pathway, such as interleukin-1 receptor-associated kinase 4 deficiency, h

148 R4-mediated signaling pathway (reduced MyD88-interleukin-1 receptor-associated kinase [IRAK] interact

149 l as GD1a itself inhibited flagellin-induced interleukin-1 receptor-associated kinase activation as w

150 nitude of flagellin signaling as measured by interleukin-1 receptor-associated kinase activation or t

151 Abs induced activation of TLR4 and triggered interleukin-1 receptor-associated kinase phosphorylation

152 main containing adaptor protein)-MyD88-IRAK (interleukin-1 receptor-associated kinase)1/4-TRAF6 (TNF

153 had impaired S aureus-induced activation of interleukin-1 receptor-associated kinase, c-Jun NH2 term

154 o-1 actions were likely to be independent of interleukin-1 receptor-associated kinase-1 (IRAK-1) regu

155 miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an

156 h diminished IL-1beta-induced degradation of interleukin-1 receptor-associated kinase-1 (IRAK-1).

157 pression, myeloid differentiation factor 88, interleukin-1 receptor-associated kinase-1, and nuclear

158 Interleukin-1 receptor-associated kinase-4 (IRAK-4) is a

159 Within innate immune signaling pathways, interleukin-1 receptor-associated kinases (IRAKs) fulfil

160 its DD and TIR domain and interacts with the interleukin-1 receptor-associated kinases (IRAKs) to for

161 LR-signaling molecules MyD88, IRAK-1 (type I interleukin-1 receptor-associated protein kinase), and T

162 In this subgroup analysis, interleukin-1 receptor blockade was associated with sign

163 ctivation syndrome features may benefit from interleukin-1 receptor blockade.

164 entricular assist device, treatment with the interleukin-1 receptor blocking agent anakinra 100 mg/d

165 nt with fulminant viral myocarditis with the interleukin-1 receptor blocking agent anakinra.

166 ride, suggesting a specific role for TFF2 in interleukin 1 receptor but not Toll-like receptor 4 sign

167 ma infection than wild-type, Dectin-1-/-, or interleukin 1 receptor-deficient (IL-1R-/-) mice.

168 Interleukin-1 receptor-deficient (IL-1R(-/-)) mice are h

169 le nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that

170 ed the hypothesis that polymorphisms in Toll-interleukin 1 receptor domain containing adaptor protein

171 ctivate downstream signaling via TIRAP (Toll-interleukin 1 receptor domain containing adaptor protein

172 ne spanning region and an intracellular Toll/Interleukin 1 receptor domain which invokes signal trans

173 d differentiation factor 88 (MyD88) and toll/interleukin 1 receptor domain-containing adapter inducin

174 d differentiation factor 88 (MyD88) and Toll-interleukin 1 receptor domain-containing adapter inducin

175 8-independent TLR signals by inhibiting Toll/interleukin 1 receptor domain-containing adaptor inducin

176 was myeloid differentiation factor 88-, Toll-interleukin 1 receptor domain-containing adaptor inducin

177 rimary response protein 88 (MyD88), and Toll interleukin 1 receptor domain-containing adaptor protein

178 ndicating that the Toll-6 receptor, the Toll/interleukin-1 receptor domain adaptor dSARM, and FoxO fu

179 -protein ligase that interacts with the Toll/interleukin-1 receptor domain of TLRs and promotes their

180 Pharmacologic and genetic disruption of Toll/interleukin-1 receptor domain-containing adapter inducin

181 Recent studies suggest that a Toll/interleukin-1 receptor domain-containing adapter protein

182 The TLR adaptor Toll/interleukin-1 receptor domain-containing adapter-inducin

183 d differentiating factor 88 (MyD88) and Toll/interleukin-1 receptor domain-containing adapter-inducin

184 , such as Cardif/MAVS/IPS-1/VISA, TRIF (Toll-interleukin-1 receptor domain-containing adaptor inducin

185 g RNA knockdown of TLR3 or its adaptor, Toll-interleukin-1 receptor domain-containing adaptor inducin

186 cell line Mono Mac 6, induction of the Toll-interleukin-1 receptor domain-containing adaptor-inducin

187 duced autophagy was regulated through a Toll-interleukin-1 receptor domain-containing adaptor-inducin

188 production of ETs by S cells requires a Toll/Interleukin-1 receptor domain-containing protein TirA an

189 Toll/interleukin-1-receptor domain containing adaptor protein

190 ring RNA, and macrophages isolated from Toll/interleukin-1 receptor-domain-containing adaptor inducin

191 e deficient in the TLR adaptor proteins Toll/interleukin-1 receptor-domain-containing adaptor protein

192 r the SAM (sterile alpha motif) or TIR (Toll-interleukin-1 receptor) domains abolishes the ability of

193 the patient-specific characteristics of the interleukin-1 receptor family member ST2 in patients wit

194 s to examine the value of measurement of the interleukin-1 receptor family member ST2 in patients wit

195 Serum levels of the interleukin-1 receptor family member ST2 predict mortali

196 Four biomarkers, soluble form of ST2 (an interleukin-1 receptor family member), galectin-3, matri

197 ST2 is a member of the interleukin-1 receptor family with a soluble form that i

198 The interleukin-1 receptor I (IL-1RI) is critical for host r

199 chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor

200 The interleukin 1 receptor (IL-1R) and the Toll-like recepto

201 activation is mediated through TRAF6 in the interleukin 1 receptor (IL-1R) and toll-like receptor (T

202 h their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathwa

203 LLIP) regulates Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling against mycobac

204 rotein is critical in Toll-like receptor and interleukin 1 receptor (IL-1R) signaling, but has not be

205 ive influenza A virus, signaling through the interleukin 1 receptor (IL-1R) was required for producti

206 DA-5), as well as cytokine receptors such as interleukin 1 receptor (IL-1R), have been implicated in

207 ffects of pretreatment with an antagonist of interleukin 1 receptor (IL-1Ra).

208 ated innate signaling pathway, as well as in interleukin-1 receptor (IL-1R) and IL-18R signaling.

209 Stimulation through the interleukin-1 receptor (IL-1R) and some Toll-like recept

210 d was first characterized as an inhibitor of interleukin-1 receptor (IL-1R) and Toll-like receptor (T

211 Both interleukin-1 receptor (IL-1R) and toll-like receptor 2

212 members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) families transduce signal

213 ta (IkappaBzeta), a Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) inducible transcription f

214 ), a negative regulator of the Toll-like and interleukin-1 receptor (IL-1R) signaling pathways, contr

215 Here we show that interleukin-1 receptor (IL-1R) signaling protects mice f

216 e expression of the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily, IL-1beta pro

217 Surprisingly, the interleukin-1 receptor (IL-1R) was required for an AEC c

218 ting microglia expressed high amounts of the interleukin-1 receptor (IL-1R), and treatment with an IL

219 a signaling adaptor shared by most TLRs and interleukin-1 receptor (IL-1R), in an in vitro model of

220 c expression of toll-like receptor 4 (TLR4), interleukin-1 receptor (IL-1R), or interferon-gamma rece

221 Interleukin-1 receptor (IL-1R)-associated kinase (IRAK)

222 We identified interleukin-1 receptor (IL-1R)-associated kinase 1 (IRAK

223 However, both MyD88-deficient mice and interleukin-1 receptor (IL-1R)-deficient mice failed to

224 fied nearly two decades ago as a mediator of interleukin-1 receptor (IL-1R)-mediated activation of NF

225 ponses are controlled through members of the interleukin-1 receptor (IL-1R)/Toll-like receptor superf

226 The type 1 interleukin-1 receptor (IL-1R1) mediates diverse functio

227 Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) have TIR intracellular

228 in that links toll-like receptors (TLRs) and Interleukin-1 receptors (IL-1Rs) with downstream signali

229 evoked by the Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs).

230 D88(-/-), MyD88/TLR adaptor molecule 1(-/-), interleukin-1 receptor [IL-1R1](-/-), and interleukin (I

231 00 [UL = unique long]) and host-genes (e.g., interleukin-1 receptor, IRF1).

232 -/-)), caspase-1 knockout (Casp-1(-/-)), and interleukin-1 receptor knockout (IL-1R(-/-)) mice treate

233 We have reported that signaling in interleukin-1-receptor-knockout (IL-1R1(-/-)) mice leads

234 ivates many immune cell types expressing the interleukin 1 receptor-like 1 (IL1RL1) receptor ST2, inc

235 hil C-C chemokine receptor type 3 (CCR3) and interleukin 1 receptor-like 1 (ST2) in vivo.

236 dipocyte differentiation, whereas Got2, Cpq, interleukin-1 receptor-like 1/ST2-IL-33, Sparc, and Lgal

237 Interleukin-1-receptor-like-1 (IL1RL1 or ST2) is a well-

238 because deletion of Nlrp3, caspase-1 and the interleukin-1 receptor markedly protects against rheumat

239 uide cleavage of transcripts of the Toll and Interleukin-1 receptor-NB-LRR immune receptor N from tob

240 r-triggered immunity conditioned by the Toll Interleukin-1 Receptor-nucleotide binding (NB)-Leu-rich

241 gered immunity specifically mediated by Toll-interleukin-1 receptor-nucleotide binding-leucine-rich r

242 RCT1 is a member of the Toll-interleukin-1 receptor/nucleotide-binding site/leucine-r

243 all genes predicted to contain either a Toll/interleukin-1 receptor or nucleotide-binding site domain

244 Single-immunoglobulin interleukin-1 receptor-related (SIGIRR), which is also k

245 rphan receptor SIGIRR (single immunoglobulin interleukin-1 receptor-related protein) acts as a negati

246 on between the transmembrane domain and Toll-interleukin 1 receptor resistance (TIR) domain.

247 Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of

248 mmune responses that was independent of Toll-Interleukin 1 Receptor signaling and directed toward det

249 In Toll-like receptor and interleukin-1 receptor signaling pathways, the kinase IR

250 mon adaptor for toll-like receptor (TLR) and Interleukin-1 receptor signaling, are critical for radio

251 -1 activity in bone marrow-derived cells and interleukin-1 receptor signaling.

252 rotein that mediates Toll-like receptors and interleukin-1 receptor signaling.

253 ucially relies on the Nlrp3 inflammasome and interleukin-1 receptor signalling.

254 ignaling by the toll-like receptor (TLR) and interleukin-1 receptor superfamily requires the adapter

255 ch signal through adaptors containing a Toll-interleukin 1 receptor (TIR) domain, such as MyD88 and T

256 TRIF is a Toll-interleukin 1 receptor (TIR) domain-containing adapter p

257 n primary response gene 88 (MyD88)- and Toll-interleukin 1 receptor (TIR) domain-containing adaptor i

258 Here, we describe a Toll/interleukin 1 receptor (TIR) domain-containing protein (

259 SENSITIVE 3 (CHS3) encodes an atypical Toll/Interleukin 1 Receptor (TIR)-type NLR protein with an ad

260 Herein, by using the toll/interleukin-1 receptor (TIR) domain homologous C-termina

261 abase for proteins with homology to the Toll/interleukin-1 receptor (TIR) domain of the mammalian Tol

262 The Toll/Interleukin-1 receptor (TIR) domain of the Toll-like rec

263 The Toll/interleukin-1 receptor (TIR) domain plays a crucial role

264 A Toll/interleukin-1 receptor (TIR) domain protein, TirA, was a

265 rly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cel

266 e-rich repeat (NLR) protein with a Toll-like interleukin-1 receptor (TIR) domain, which mediates XopQ

267 Toll/interleukin-1 receptor (TIR) domain-containing adapter p

268 lipopolysaccharide, this is a delayed, Toll/interleukin-1 receptor (TIR) domain-containing adapter-i

269 esponses by targeted degradation of the Toll/interleukin-1 receptor (TIR) domain-containing adaptor p

270 ckouts including TLR2, TLR4, MyD88, and Toll-interleukin-1 receptor (TIR) domain-containing adaptor p

271 Toll-interleukin-1 receptor (TIR) domain-containing adaptor-i

272 Toll/interleukin-1 receptor (TIR) domain-containing adaptors

273 L6 is a Toll/interleukin-1 receptor (TIR) domain-containing NLR from

274 The Toll-interleukin-1 receptor (TIR) domain-containing orphan re

275 ults in dimerization of their cytosolic Toll/interleukin-1 receptor (TIR) domains and recruitment of

276 Toll-like receptors (TLRs), cytoplasmic Toll/interleukin-1 receptor (TIR) domains of the receptors un

277 The heterotypic interaction between the Toll/interleukin-1 receptor (TIR) domains of TLRs and adaptor

278 aling adapter protein interactions with Toll/Interleukin-1 Receptor (TIR) domains present in sensory

279 effectors through adaptors that contain Toll/interleukin-1 receptor (TIR) domains, but the mechanisms

280 signaling by dimerizing the cytoplasmic Toll interleukin-1 receptor (TIR) domains.

281 Analysis of Toll/interleukin-1 receptor (TIR) sequences indicated that th

282 illo motif (SARM) is a highly conserved Toll/interleukin-1 receptor (TIR)-containing adaptor protein

283 structures of MAL revealed a nontypical Toll/interleukin-1 receptor (TIR)-domain fold stabilized by t

284 equires the P loops of each protein and Toll/interleukin-1 receptor (TIR)-domain-mediated heteromeric

285 in Brescia (BICv) identified a putative Toll/interleukin-1 receptor (TIR)-like domain.

286 The majority of these belong to the Toll/Interleukin-1 receptor (TIR)-NBS-LRR (TNL) class.

287 lays an essential role in Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) -associated NF-kappaB

288 can activate signaling by the Toll-like and interleukin-1 receptors (TLR and IL-1R) to mediate patho

289 signalling (tumour necrosis factor receptor/interleukin-1 receptor, TNFR/IL-1R in mammals) is indisp

290 ch are adaptor molecules that couple TNF and interleukin-1 receptor/Toll-like receptor family members

291 mediating signals from both TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies.

292 am of many receptors in the TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies.

293 he negative regulation of Toll-like receptor/interleukin-1 receptor-triggered inflammatory cascades a

294 was developed to analyze recombinant soluble Interleukin 1 receptor type II (sIL-1R type II) drug sub

295 d the role of toll-like receptors (TLRs) and interleukin-1 receptor type 1 (IL-1R1) in S. marcescens-

296 nization, we show that mice deficient in the interleukin-1 receptor type 1 (Il1r1(-/-)) have reduced

297 y protein (IL1RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregul

298 Interleukin-1 receptor type 2 (IL1R2) acts as a decoy re

299 Interleukin-1 receptor type I knockout mice, which displ

300 In the study of recombinant human Interleukin-1 receptor type II (rhuIL-1R(II)) aggregatio